适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
To request access, use Responsible Party contact information provided in this record.
Expanded access for tipifarnib is only available in the United States.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- •Adult, ages 18+.
- •Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
- •Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
- •Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
研究者
相似试验
Available
不适用
Expanded Access to ZiftomenibAcute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 MutationsAcute Lymphoblastic Leukemia, With KMT2A RearrangementsAcute Myeloid Leukemia, With KMT2A RearrangementsNCT05738538Kura Oncology, Inc.
Unknown
不适用
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesNCT03631056Humacyte, Inc.
Available
不适用
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate CancerNCT05650476Pfizer
Available
不适用
Individual Patient Compassionate Use of FedratinibMyelofibrosisNCT03723148Celgene
Available
不适用
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Alopecia AreataNCT05522556Pfizer